​

BeOne Medicines (ONC) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ONC Stock Forecast


BeOne Medicines (ONC) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $426.50, with a high of $470.00 and a low of $370.00. This represents a 5.67% increase from the last price of $403.60.

$250 $300 $350 $400 $450 $500 High: $470 Avg: $426.5 Low: $370 Last Closed Price: $403.6

ONC Stock Rating


BeOne Medicines stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 15 Strong Sell Sell Hold Buy Strong Buy

ONC Price Target Upside V Benchmarks


TypeNameUpside
StockBeOne Medicines5.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts1524
Avg Price Target$470.00$437.80$409.67
Last Closing Price$403.60$403.60$403.60
Upside/Downside16.45%8.47%1.50%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 267191--27
Oct, 267201--28
Sep, 267201--28
Aug, 26820---28
Jul, 268191--28
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2026Faisal KhurshidJefferies$470.00$391.2820.12%16.45%
Oct 16, 2026Sean LaamanMorgan Stanley$425.00$368.0815.46%5.30%
Oct 08, 2026RBC Capital$459.00$341.1034.56%13.73%
Oct 07, 2026Gregory RenzaTruist Financial$420.00$365.2115.00%4.06%
Sep 10, 2026Barclays$415.00$351.0018.23%2.82%
Aug 10, 2026Kalpit PatelWolfe Research$370.00$358.383.24%-8.33%
Aug 06, 2026Barclays$407.00$327.5324.26%0.84%
Jul 14, 2026Barclays$403.00$303.9632.58%-0.15%
Jul 13, 2026Jefferies$380.00$298.7027.22%-5.85%
Jul 07, 2026Truist Financial$416.00$308.4634.86%3.07%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2026JefferiesBuyBuyhold
Oct 16, 2026Morgan StanleyOverweightOverweighthold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Sep 10, 2026BarclaysOverweightOverweighthold
Aug 10, 2026Wolfe ResearchOutperformOutperformhold
Aug 06, 2026Morgan StanleyOverweightOverweighthold
Aug 06, 2026CitigroupBuyBuyhold
Aug 06, 2026CitigroupOutperformOutperformhold
Aug 06, 2026BarclaysOverweightOverweighthold
Jul 13, 2026JefferiesBuyPositiveupgrade

Financial Forecast


EPS Forecast

$-10 $-1 $8 $17 $26 $35 Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-6.12$34.19-
Avg Forecast$-5.83$-0.02$5.53
High Forecast$-5.20$2.11$8.75
Low Forecast$-6.62$-3.52$0.75
Surprise %4.97%-171050.00%-

Revenue Forecast

$4B $4B $5B $6B $7B $8B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$3.81B$5.34B-
Avg Forecast$3.77B$4.84B$5.98B
High Forecast$3.78B$4.96B$7.00B
Low Forecast$3.75B$4.71B$5.02B
Surprise %1.07%10.39%-

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-644.79M$286.93M-
Avg Forecast$-613.83M$-2.11M$582.26M
High Forecast$-547.50M$222.16M$921.72M
Low Forecast$-697.01M$-370.61M$78.97M
Surprise %5.04%-13726.08%-

ONC Forecast FAQ


Is BeOne Medicines stock a buy?

BeOne Medicines stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BeOne Medicines is a favorable investment for most analysts.

What is BeOne Medicines's price target?

BeOne Medicines's price target, set by 15 Wall Street analysts, averages $426.5 over the next 12 months. The price target range spans from $370 at the low end to $470 at the high end, suggesting a potential 5.67% change from the previous closing price of $403.6.

How does BeOne Medicines stock forecast compare to its benchmarks?

BeOne Medicines's stock forecast shows a 5.67% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BeOne Medicines over the past three months?

  • November 2026: 25.93% Strong Buy, 70.37% Buy, 3.70% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 25.00% Strong Buy, 71.43% Buy, 3.57% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 71.43% Buy, 3.57% Hold, 0% Sell, 0% Strong Sell.

What is BeOne Medicines’s EPS forecast?

BeOne Medicines's average annual EPS forecast for its fiscal year ending in December 2026 is $5.53, marking a -83.83% decrease from the reported $34.19 in 2025..

What is BeOne Medicines’s revenue forecast?

BeOne Medicines's average annual revenue forecast for its fiscal year ending in December 2026 is $5.98B, reflecting a 11.90% increase from the reported $5.34B in 2025.

What is BeOne Medicines’s net income forecast?

BeOne Medicines's net income forecast for the fiscal year ending in December 2026 stands at $582.26M, representing an 102.92% increase from the reported $286.93M in 2025.